GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » Dividend-Payout-to-FFO

Hua Medicine (HKSE:02552) Dividend-Payout-to-FFO


View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Hua Medicine (HKSE:02552) Business Description

Traded in Other Exchanges
N/A
Address
Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in development and commercialization of a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC. Some of its products are Dorzagliatin + Metformin, Dorzagliatin, Dorzagliatin + Pioglitazone and mGLUR5 NAM, among others.